spacer
home > ebr > summer 2020 > beyond big data
PUBLICATIONS
European Biopharmaceutical Review

Beyond Big Data

We’ve all seen and experienced the benefits that Big Data have brought to machine learning. Computers have become good at tasks like understanding human language and interpreting images – self-driving cars are arguably one of the most impressive examples.

Big Data mean that you have millions, if not billions, of observations and for each observation you have a manageable amount of data. For instance, when data scientists analyse Twitter data they have hundreds of millions of tweets; however, each tweet is less than 280 characters. In a nutshell, Big Data are when you want to learn something simple and you have an abundance of examples.

Most machine learning techniques work more efficiently when Big Data are provided. The availability of Big Data can sometimes eclipse the algorithms used. You might know the Modified National Institute of Standards and Technology data – they’re a large number of images (around 50,000) of hand-written digits (zero to nine) and tons of machine learning tutorials use this data set. Even the most basic machine learning models can identify 97% of the digits correctly. With complicated deep nets, you get up to 99.7% accuracy – showing how the most sophisticated artificial intelligence (AI) algorithm provides a whopping 2.7% increase.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Joern Klinger is a developmental psychologist, computational linguist, geneticist, and entrepreneur. During his graduate studies in Oxford and Texas, Joern investigated human cognition in order to optimise AI. Insights from hands-on research in an indigenous community, neural-networks, and agent models led to an outside-the-box machine learning understanding, which he’s applying at his start-up biotx.ai.
spacer
Joern Klinger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SEKISUI XenoTech Receives New US Patent for a Method to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Hepatocytes

Kansas City, KS- SEKISUI XenoTech has been awarded US patent # 10,648,968 “In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes.”
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement